Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05642780
Title SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Klus Pharma Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN | BEL | AUS


No variant requirements are available.